All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @daniellenstanton on TikTok · 70s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @daniellenstanton's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00I've had a lot of questions about hair loss and testosterone, so let's talk about it.
  2. 0:05What's interesting is I hear this a lot, but I don't think people realize low testosterone
  3. 0:11actually causes hair loss.
  4. 0:14So you might be experiencing hair loss without even the injections or testosterone cream or
  5. 0:21pellets.
  6. 0:22This is something to talk to your doctor about.
  7. 0:25It's also about the dose.
  8. 0:27Staying.
  9. 0:28You say, slow and steady, don't do any high doses because you don't want to have any side
  10. 0:35effects.
  11. 0:36I'm not worried about the side effects because I'm working with my doctor.
  12. 0:39I'm taking it slow and I'm very careful.
  13. 0:43And we're monitoring my lab work every three months, so we have an idea of how I'm doing
  14. 0:49and how I'm responding to all the hormones.
  15. 0:52When you're on hormone replacement, you need to be consistently checking your labs and consistently
  16. 0:58talking to your doctor about concerns and side effects.
  17. 1:02This is really important.
  18. 1:03That's why it's important to find that doctor that will take all these questions and support
  19. 1:08you during this time.

Testosterone for perimenopause: what TikTok gets wrong

danielle stanton

TikTok creator

2.3K viewsWatch on TikTok

Quick answer

Testosterone therapy in perimenopausal women is an off-label use in the US, typically initiated for hypoactive sexual desire disorder or fatigue when other causes have been ruled out. Hair changes, both loss and growth in unwanted areas, are among the most frequently reported side effects and are mediated primarily through DHT conversion rather than testosterone directly. Monitoring should include total and free testosterone, SHBG, DHT, and a full metabolic panel at baseline and at regular intervals after initiation.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

TRT social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Testosterone for perimenopause: what TikTok gets wrong, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Video claim decision path

Turn the claim into a safer next question

Direct answer

Testosterone for perimenopause: what TikTok gets wrong should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.

Claim path

Keep researching this testosterone and trt video claims cluster

Best for searchers turning TRT social claims into a safer lab-backed provider discussion.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "Testosterone for perimenopause: what TikTok gets wrong" from danielle stanton. We read the clip as a TRT social video fact-checks claim about Testosterone, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Testosterone therapy in perimenopausal women is an off-label use in the US, typically initiated for hypoactive sexual desire disorder or fatigue when other causes have been ruled out.

The reason this review is not generic is the source wording and the canonical claim label "trt replying to annette way hrt perimenopause hormoneimbalance h." In this clip, the useful excerpt is: "I've had a lot of questions about hair loss and testosterone, so let's talk about it." That wording changes the review because it points to Testosterone evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Cardiovascular Safety of Testosterone-Replacement Therapy (2023), Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline (2010), and Functional testosterone deficiency in aging men: Clinical impact, diagnostic pathways, and treatment strategies (2026), plus the creator's own wording. Testosterone decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

DHT, not testosterone itself, drives androgenetic alopecia in genetically susceptible individuals.
People who land here are usually comparing the Testosterone claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Testosterone guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Testosterone therapy in perimenopausal women is an off-label use in the US, typically initiated for hypoactive sexual desire disorder or fatigue when other causes have been ruled out.

FormBlends verdict

Testosterone evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Testosterone therapy in perimenopausal women is an off-label use in the US, typically initiated for hypoactive sexual desire disorder or fatigue when other causes have been ruled out. Hair changes, both loss and growth in unwanted areas, are among the most frequently reported side effects and are mediated primarily through DHT conversion rather than testosterone directly. Monitoring should include total and free testosterone, SHBG, DHT, and a full metabolic panel at baseline and at regular intervals after initiation.
  • Low testosterone is genuinely associated with diffuse hair thinning in women, but so are thyroid dysfunction, low ferritin, and estrogen shifts common in perimenopause. Get a full panel before attributing hair loss to one hormone.
  • DHT, not testosterone itself, drives androgenetic alopecia in genetically susceptible individuals. Trüeb (2018, International Journal of Trichology) confirmed testosterone receptor activity in follicles affects the growth cycle in both directions.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • Low testosterone is genuinely associated with diffuse hair thinning in women, but so are thyroid dysfunction, low ferritin, and estrogen shifts common in perimenopause. Get a full panel before attributing hair loss to one hormone.
  • DHT, not testosterone itself, drives androgenetic alopecia in genetically susceptible individuals. Trüeb (2018, International Journal of Trichology) confirmed testosterone receptor activity in follicles affects the growth cycle in both directions.
  • Glaser and Dimitrakakis (2020, Maturitas) found that testosterone pellet therapy raised DHT significantly in women, and hair loss was among the most commonly reported adverse effects in sensitive patients.
  • The Endocrine Society recommends checking testosterone levels 3 to 6 weeks after starting therapy, then every 3 months until stable. The creator's quarterly monitoring claim aligns with published guidelines.
  • Testosterone therapy for women is off-label in the US. No FDA-approved testosterone product for women currently exists, which means compounded and repurposed products dominate this space and carry additional variability in dosing.
  • Faubion et al. (2021, Menopause) found that women with access to engaged, communicative providers report better symptom management outcomes. The creator's advice to find a supportive doctor is backed by real data.
  • If you are concerned about testosterone-related hair loss, asking your provider to measure baseline DHT before starting therapy gives you a concrete reference point for any changes that follow.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @daniellenstanton actually say?

The creator made three core claims: that low testosterone itself can cause hair loss (not just testosterone therapy), that slow and steady dosing reduces side effects, and that consistent lab monitoring every three months is the right way to manage hormone replacement. These are all reasonable starting points, though some need more nuance than a short TikTok can offer.

She was replying to a question about hair loss and testosterone, which is one of the most common fears people bring to perimenopause conversations. Her framing, "low testosterone actually causes hair loss," is the most medically interesting claim here, and it deserves a proper look rather than a quick dismissal.

Does the science back this up?

Partially, yes. The relationship between testosterone and hair loss is genuinely bidirectional, and that part is accurate. But the mechanism is more complicated than the video implies, and anyone making decisions based on this clip should know the full picture.

The hair loss most people associate with testosterone therapy is androgenetic alopecia, driven by dihydrotestosterone (DHT), a metabolite of testosterone. Higher testosterone levels can mean more substrate for DHT conversion via the 5-alpha reductase enzyme. That is the conventional concern.

But the creator is right that hypogonadism, meaning clinically low testosterone, is also associated with hair changes. A 2018 review by Trüeb in the International Journal of Trichology noted that testosterone receptors are present in hair follicles, and that both deficiency and excess can disrupt the hair growth cycle. Low testosterone in women has been linked to diffuse hair thinning, particularly in postmenopausal and perimenopausal populations. So saying low testosterone "causes" hair loss is not wrong, but it oversimplifies a dose-response relationship that depends heavily on individual genetics, DHT sensitivity, and baseline hormone levels.

What did they get wrong (or right)?

She got the bidirectional nature of testosterone and hair loss basically right, which is more than most TikTok creators manage on this topic. The advice to "stay slow and steady" with dosing is also consistent with clinical guidance, though framing it as purely a side-effect-avoidance strategy undersells the real reason: it allows for accurate dose titration and reduces the risk of supraphysiologic levels, which carry their own consequences including, ironically, accelerated hair loss.

Where the video falls short is that it does not mention DHT at all. Anyone watching this who has a genetic predisposition to androgenetic alopecia needs to know that even modest testosterone increases can accelerate hair loss through DHT conversion, regardless of how careful their dosing is. A 2020 study by Glaser and Dimitrakakis in Maturitas found that testosterone pellet therapy in women significantly increased DHT levels, and that hair loss was among the most commonly reported adverse effects in sensitive individuals. Omitting this is not dangerous misinformation, but it is an incomplete picture.

Her point about lab monitoring every three months is solid. That is consistent with Endocrine Society clinical practice guidelines for women on testosterone therapy.

What should you actually know?

If you are in perimenopause and experiencing hair loss, testosterone is one variable on a long list that includes thyroid function, ferritin levels, estrogen, prolactin, and autoimmune conditions. Assuming it is low testosterone without labs is a mistake.

If you are considering testosterone therapy and worried about hair, the honest answer is that risk depends on your genetics and your DHT conversion rate. Testing baseline DHT before starting therapy gives you and your doctor something to compare against. Some providers add a 5-alpha reductase inhibitor for patients who show DHT elevation after starting testosterone, though that comes with its own considerations.

The creator's emphasis on finding a doctor who will engage with your questions and run labs consistently is genuinely good advice. A 2021 survey published in Menopause by Faubion and colleagues found that a significant proportion of women report their symptoms being dismissed by providers, and that care quality improves meaningfully when patients have access to a knowledgeable, communicative clinician. That part of the video is worth taking seriously.

  • Hair loss on testosterone therapy is not inevitable, but it is also not just a dosing problem.
  • DHT, not testosterone directly, is typically the driver of scalp hair loss in genetically susceptible individuals.
  • Low testosterone can cause diffuse hair thinning, but so can thyroid disorders, iron deficiency, and estrogen changes common in perimenopause.
  • Quarterly lab monitoring is consistent with Endocrine Society recommendations for women on testosterone therapy.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

danielle stanton · TikTok creator

2.3K views on this video

Replying to @Annette Way #hrt #perimenopause #hormoneimbalance #hormones #fypシ゚viral

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about low testosterone?

Low testosterone is genuinely associated with diffuse hair thinning in women, but so are thyroid dysfunction, low ferritin, and estrogen shifts common in perimenopause. Get a full panel before attributing hair loss to one hormone.

What does the video say about dht, not testosterone itself, drives?

DHT, not testosterone itself, drives androgenetic alopecia in genetically susceptible individuals. Trüeb (2018, International Journal of Trichology) confirmed testosterone receptor activity in follicles affects the growth cycle in both directions.

What does the video say about glaser?

Glaser and Dimitrakakis (2020, Maturitas) found that testosterone pellet therapy raised DHT significantly in women, and hair loss was among the most commonly reported adverse effects in sensitive patients.

What does the video say about the endocrine society recommends checking testosterone levels 3 to 6?

The Endocrine Society recommends checking testosterone levels 3 to 6 weeks after starting therapy, then every 3 months until stable. The creator's quarterly monitoring claim aligns with published guidelines.

What does the video say about testosterone therapy for women?

Testosterone therapy for women is off-label in the US. No FDA-approved testosterone product for women currently exists, which means compounded and repurposed products dominate this space and carry additional variability in dosing.

What does the video say about faubion et al. (2021, menopause) found?

Faubion et al. (2021, Menopause) found that women with access to engaged, communicative providers report better symptom management outcomes. The creator's advice to find a supportive doctor is backed by real data.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Not medical advice. This video was made by danielle stanton, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.